Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Literacy to Focused Pharmacovigilance

The legacy domain of general health and science information provided a broad foundation for public understanding of medical conditions and therapeutic interventions. Within this context, audiences became familiar with the basic principles of drug safety, adverse event reporting, and the importance of clinical evidence in evaluating treatment risks. This general awareness naturally extends to more specific inquiries, such as the relationship between bisphosphonate therapy and rare but serious complications. The transition from broad health literacy to focused pharmacovigilance is exemplified by the target query concerning Fosamax and osteonecrosis of the jaw. This pivot moves from abstract knowledge of drug side effects to a concrete, clinically documented adverse outcome associated with a widely prescribed medication. The bridge concept thus reframes general health awareness into a targeted examination of exposure risk, where the clinical evidence review becomes the central tool for understanding causation. This shift emphasizes the need for rigorous data analysis, moving beyond general health tips to the precise evaluation of drug-specific safety profiles. The occupational exposure concern, while not the primary focus here, emerges as a parallel consideration when assessing prolonged or high-dose exposure scenarios in clinical populations.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the foundation of general health literacy, we now turn to a specific clinical question: Does Fosamax (alendronate sodium) cause osteonecrosis of the jaw (ONJ)? Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well-established, but a serious adverse effect—osteonecrosis of the jaw—has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This review examines the clinical evidence linking Fosamax to ONJ, including presentation, mechanistic pathways, risk factors, and causation considerations.

Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw

ONJ is defined as exposed necrotic bone in the maxillofacial region that persists for more than eight weeks in the absence of prior radiation therapy. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation includes pain, swelling, purulent discharge, and exposed bone in the jaw. Diagnosis is primarily clinical, supported by imaging such as panoramic radiographs or CT scans. The multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research underscores the unique susceptibility of the jawbone to bisphosphonate-induced pathology.

Fosamax Pharmacology and Reported Adverse Effects

Fosamax is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. It is indicated for conditions characterized by increased bone turnover, such as postmenopausal osteoporosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined; for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Adverse effects include gastrointestinal symptoms, musculoskeletal pain, and, notably, ONJ. In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, postmarketing reports have identified ONJ as a rare but serious adverse event.

Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw

The pathogenesis of bisphosphonate-related ONJ is multifactorial. Bisphosphonates accumulate in bone, particularly at sites of high turnover such as the jaw. They inhibit osteoclast activity, which can impair bone remodeling and repair. This suppression of bone turnover may lead to microdamage accumulation and necrosis. Additionally, bisphosphonates have anti-angiogenic properties, reducing blood supply to the jawbone. The jawbone's unique structure and high remodeling rate make it especially vulnerable (https://pubmed.ncbi.nlm.nih.gov/40345077/). Local factors such as dental procedures, infection, and inflammation further compromise healing, precipitating ONJ.

Risk Factors and Adequacy of Warnings

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The prescribing information for Fosamax includes a warning about ONJ, stating that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the adequacy of these warnings has been questioned, as ONJ may occur in patients without known risk factors, and the label does not specify the magnitude of risk or provide detailed guidance on dental monitoring.

Causation-Related Considerations for Affected Patients

Establishing causation between Fosamax and ONJ requires careful evaluation of temporal relationship, exclusion of other causes, and biological plausibility. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal role. However, ONJ can also occur spontaneously, and many patients have concurrent risk factors such as dental disease or cancer therapy. For affected patients, a thorough history of bisphosphonate use, dental procedures, and comorbidities is essential. The label advises discontinuation of Fosamax if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Timeline Between Exposure and Documented Harm

The timeline for ONJ development is variable. Symptoms may appear as early as one day after starting Fosamax or after several months of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk increases with longer duration of bisphosphonate therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In many cases, ONJ is triggered by a dental procedure, with delayed healing leading to diagnosis. The label does not provide a specific latency period, but postmarketing data suggest that most cases occur after years of treatment, particularly in cancer patients receiving high-dose bisphosphonates. For Fosamax used at osteoporosis doses, the incidence is lower, but cases have been reported.

Conclusion

The clinical evidence supports a causal association between Fosamax and osteonecrosis of the jaw, particularly in the presence of risk factors such as dental procedures, prolonged use, and comorbidities. The prescribing information includes warnings, but the adequacy of these warnings for all patients remains a concern. Affected patients should be evaluated for temporal exposure, risk factors, and alternative causes. Discontinuation of Fosamax may reduce the risk of ONJ in patients requiring invasive dental procedures.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ)?

Osteonecrosis of the jaw is a condition characterized by exposed necrotic bone in the maxillofacial region that persists for more than eight weeks in the absence of prior radiation therapy. It can occur spontaneously but is often associated with tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How does Fosamax cause osteonecrosis of the jaw?

Fosamax, a bisphosphonate, inhibits osteoclast activity, impairing bone remodeling and repair. It also has anti-angiogenic properties, reducing blood supply to the jawbone. The jawbone's high remodeling rate makes it vulnerable. Local factors like dental procedures or infection can precipitate ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and comorbidities such as periodontal disease, anemia, or infection. The risk increases with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for ONJ to develop after starting Fosamax?

Symptoms can appear as early as one day after starting Fosamax or after several months of use. The risk increases with longer therapy duration. Most cases occur after years of treatment, especially in cancer patients on high doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.